Get 20% Free Customization In This Report

Buy this report from - $3456

Pediatrics Medicine Market by Type (Short Term Illness and Chronic Illness) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Pharmaceuticals	LI_183774	Pages: NA	Jun 2018 \| 637 Views
Author's : NA	Tables: NA	Charts: NA	Formats*:

Paediatrics medicines belong to the special category of medicines that are prescribed for the paediatrics group of patients, in different indications. These drugs are prescribed in different diseases such as anorexia, birth defects, asthma and others. Several acts such as Best Pharmaceuticals for Children Act (BPCA) and the Pediatrics Research Equity Act (PREA) has been passed to increase the R&D investments on paediatric medicines. The drivers that drive the market growth are rise in prevalence of diseases such as diabetes and obesity in children along with awareness in people. In addition, rise in government funding and awareness programs also fuel the market growth. However, low disposable income and side effects such as headache along with anxiety restraints the market growth. Technological developments in the field of paediatrics medicine will prove as a future opportunity in the market growth.

The report segments the market on the basis of type and region. Based on type, the market can be segmented into short term illness such as ear infection, upper respiratory infections & others, and chronic illness such as cystic fibrosis, diabetes and others. Regionally, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players of the market are Lupin, GlaxoSmithKline plc., Pfizer Inc., Sanofi S.A., F. Hoffman-La Roche Ltd, Abbott Laboratories, Heron Therapeutics Inc., Eli Lilly & Company, Novartis A.G, Merck Co.Ltd., and Cipla Inc.

Key Benefits

The study provides an in-depth analysis of the global pediatrics medicine market along with the current trends and future estimations to elucidate the imminent investment pockets.
Comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
Comprehensive quantitative analysis of the industry is provided for the period of 20162023 to assiststakeholders to capitalize on the prevailing market opportunities.
Extensive analysis of the key segments of the industry helps in understanding the trends in types of pediatrics medicine across the globe.
Key market players and their strategies have been provided to understand the competitive outlook of theindustry.

Pediatrics Medicine Market Key Segments:

By Type

Short Term Illness
- Ear Infection
- Upper Respiratory Infections
- Others
Chronic Illness
- Cystic Fibrosis
- Diabetes
- Others

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- UK
- France
- Germany
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- Rest of Asia-Pacific
LAMEA
- Brazil
- Turkey
- Argentina
- South Africa
- Rest of LAMEA

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. MARKET SHARE ANALYSIS/TOP PLAYER POSITIONING, 2016
3.4.PORTER’S FIVE FORCES ANALYSIS
3.5. MARKET DYNAMICS

3.5.1. Drivers
3.5.2. Restraints
356.3. Opportunities

Chapter: 4 GLOBAL PEDIATRICS MEDICINE MARKET, BY TYPE

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. SHORT TERM ILLNESS

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.2.4. Ear Infection

4.2.4.1. Market size and forecast

4.2.5. Upper Respiratory Infections

4.2.5.1. Market size and forecast

4.2.6. Others

4.2.6.1. Market size and forecast

4.3. CHRONIC ILLNESS

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
4.2.4. Cystic Fibrosis

4.3.4.1. Market size and forecast

4.3.5. Diabetes

4.3.5.1. Market size and forecast

4.3.6. Others

4.3.6.1. Market size and forecast

Chapter: 5 GLOBAL PEDIATRICS MEDICINE MARKET, BY REGION

5.1. OVERVIEW
5.2. NORTH AMERICA

5.2.1. Key market trends
5.2.2. Key growth factors and opportunities
5.2.3. Market size and forecast

5.2.3.1. U.S. market size and forecast
5.2.3.2. Canada market size and forecast
5.2.3.3. Mexico market size and forecast

5.2.4. North America Pediatric Medicine Market by Type

5.3. EUROPE

5.3.1. Key market trends
5.3.2. Key growth factors and opportunities
5.3.3. Market size and forecast

5.3.3.1. Germany market size and forecast
5.3.3.2. France market size and forecast
5.3.3.3. UK market size and forecast
5.3.3.4. Italy market size and forecast
5.3.3.5. Spain market size and forecast
5.3.3.6. Rest of Europe market size and forecast

5.3.4. Europe Pediatrics Medicine Market by Type

5.4. ASIA-PACIFIC

5.4.1. Key market trends
5.4.3. Key growth factors and opportunities
5.4.3. Market size and forecast

5.4.3.1. Japan market size and forecast
5.4.3.3. China market size and forecast
5.4.3.3. Australia market size and forecast
5.4.3.4. India market size and forecast
5.4.3.7. Rest of Asia-Pacific market size and forecast

5.4.4. Asia-Pacific Pediatric Medicine Market by Type

5.5. LAMEA

5.5.1. Key market trends
5.5.3. Key growth factors and opportunities
5.5.3. Market size and forecast

5.5.3.1. Brazil market size and forecast
5.5.3.3. Turkey market size and forecast
5.5.3.3. Argentina market size and forecast
5.5.3.4. South Africa market size and forecast
5.5.3.5. Rest of LAMEA market size and forecast

5.5.4. LAMEA Pediatric Medicine Market by Type

Chapter: 6 COMPANY PROFILES

6.1. LUPIN

6.1.1. Operating business segments
6.1.3. Business performance
6.1.3. Key strategic moves and developments

6.3. GLAXOSMITHKLINE PLC

6.3.1. Operating business segments
6.3.3. Business performance
6.3.3. Key strategic moves and developments

6.3. PFIZER INC.

6.3.1. Operating business segments
6.3.3. Business performance
6.3.3. Key strategic moves and developments

6.4. SANOFI S.A.

6.4.1. Operating business segments
6.4.3. Business performance
6.4.3. Key strategic moves and developments

6.5. F.HOFFMAN-LA ROCHE LTD.

6.5.1. Operating business segments
6.5.3. Business performance
6.5.3. Key strategic moves and developments

6.6. ABBOTT LABORATORIES

6.6.1. Operating business segments
6.6.3. Business performance
6.6.3. Key strategic moves and developments

6.7. HERON THERAPEUTICS, INC.

6.7.1. Operating business segments
6.7.3. Business performance
6.7.3. Key strategic moves and developments

6.8. ELI LILLY AND COMPANY

6.8.1. Operating business segments
6.8.3. Business performance
6.8.3. Key strategic moves and developments

6.9. NOVARTIS A.G

6.9.1. Operating business segments
6.9.3. Business performance
6.9.3. Key strategic moves and developments

6.10. CIPLA INC.

6.10.1. Operating business segments
6.10.3. Business performance
6.10.3. Key strategic moves and developments

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
Technologically sophisticated and reliable insights through well audited and veracious research methodology
Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

Patent and regulatory databases for understanding of technical & legal developments
Scientific and technical writings for product information and related preemptions
Regional government and statistical databases for macro analysis
Authentic new articles, web-casts and other related releases for market evaluation
Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

Validates and improves the data quality and strengthens research proceeds
Further develops analyst team’s market understanding and expertise
Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

Chief executives and VPs of leading corporations specific to industry
Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.